Palo Alto, CANCT07354477Now EnrollingIRB Ready

Non-proliferative Diabetic Retinopathy (NPDR) Clinical Trial in Palo Alto, CA

Access cutting-edge non-proliferative diabetic retinopathy (npdr) treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Qlaris Bio, Inc.

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access non-proliferative diabetic retinopathy (npdr) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-proliferative diabetic retinopathy (npdr) treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this non-proliferative diabetic retinopathy (npdr) clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Non-proliferative Diabetic Retinopathy (NPDR) Study in Palo Alto

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Sponsor: Qlaris Bio, Inc.

Who Can Participate

Inclusion Criteria

Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.
Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20/200).
Able and willing to give signed informed consent and follow study instructions.

Exclusion Criteria

History of active ocular disease other than mild to moderate OAG, mild to moderate NTG, or stable NPDR.
Patient is using more than 1 ocular hypotensive topical medication for intraocular pressure (IOP) control (prior MIGS and/or laser trabeculoplasty to control IOP is allowed if done at least 3 months from Screening (Visit 1).
Use of TO β-blockers (i.e. timolol) within 3 months prior to Screening.
Is noncompliant with current ocular anti-hypotensive medications and/or unwilling to be compliant throughout the study.
Clinically significant severe retinal disease in either eye that will require treatment during the study (e.g., proliferative diabetic retinopathy, exudative, or severe non-exudative macular degeneration). NOTE: background diabetic retinopathy (BDR) as required for the NPDR subjects is allowed if in the Investigator's opinion the BDR is stable and is expected to remain stable during the duration of the study.
Anti-VEGF or TO steroid treatment within 3 months prior to Screening or expected treatment while participating in this study. Prior diabetic macular edema (DME) history is allowed if adequately controlled with treatment (anti-VEGFs and steroids not within last 3 months prior to Screening), regimen is stable, and not expected to change during the study. - Corneal pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, and bullae) in either eye that would inhibit accurate IOP measurements.
Previously diagnosed, clinically significant systemic or psychiatric disease (e.g., myasthenia gravis, hepatic, renal, endocrine, pulmonary, or cardiovascular disorders) which might compromise the study results or subject safety. For the purpose of this study previously diagnosed, clinically significant renal disease that should be excluded from enrollment will be defined as Stages 3-5 kidney disease and/or an estimated glomerular filtration rate (eGFR) of ≤59.
Use of calcium channel blockers.
Labile hypertension and/or hypotension that is inadequately controlled,

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT07354477) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-proliferative Diabetic Retinopathy (NPDR) Treatment Options in Palo Alto, CA

If you're searching for non-proliferative diabetic retinopathy (npdr) treatment options in Palo Alto, CA, this clinical trial (NCT07354477) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-proliferative diabetic retinopathy (npdr) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-proliferative diabetic retinopathy (npdr) clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Palo Alto, CA

See all parkinsons disease clinical trials recruiting in Palo Alto — not just this study.

Browse Parkinsons Disease Trials in Palo Alto →

Browse More Trials by Condition

Parkinsons Disease TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsType 2 Diabetes TrialsInterstitial Cystitis TrialsDiabetic Retinopathy TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA